File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/bjh.19441
- Scopus: eid_2-s2.0-85189073668
- WOS: WOS:001194924600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
| Title | Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm? |
|---|---|
| Authors | |
| Keywords | azacitidine DNA methylation epigenome hypomethylating agents myelodysplastic syndrome/neoplasm (MDS) |
| Issue Date | 2-Apr-2024 |
| Publisher | Wiley |
| Citation | British Journal of Haematology, 2024 How to Cite? |
| Abstract | Defining mechanisms of resistance to hypomethylating agents (HMAs) and biomarkers predictive of treatment response remains challenging in myelodysplastic neoplasm (MDS). Currently available prognostic tools that predict overall survival and transformation to acute myeloid leukaemia have not been powered to predict responses to HMAs. Noguera-Castells et al. comprehensively characterized the epigenomic profile in patients with MDS treated with azacitidine and described a methylation signature-based prognostic tool in predicting responses to azacitidine. |
| Persistent Identifier | http://hdl.handle.net/10722/342140 |
| ISSN | 2023 Impact Factor: 5.1 2023 SCImago Journal Rankings: 1.574 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gill, Harinder | - |
| dc.date.accessioned | 2024-04-09T07:30:02Z | - |
| dc.date.available | 2024-04-09T07:30:02Z | - |
| dc.date.issued | 2024-04-02 | - |
| dc.identifier.citation | British Journal of Haematology, 2024 | - |
| dc.identifier.issn | 0007-1048 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/342140 | - |
| dc.description.abstract | <p>Defining mechanisms of resistance to hypomethylating agents (HMAs) and biomarkers predictive of treatment response remains challenging in myelodysplastic neoplasm (MDS). Currently available prognostic tools that predict overall survival and transformation to acute myeloid leukaemia have not been powered to predict responses to HMAs. Noguera-Castells et al. comprehensively characterized the epigenomic profile in patients with MDS treated with azacitidine and described a methylation signature-based prognostic tool in predicting responses to azacitidine.</p> | - |
| dc.language | eng | - |
| dc.publisher | Wiley | - |
| dc.relation.ispartof | British Journal of Haematology | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | azacitidine | - |
| dc.subject | DNA methylation | - |
| dc.subject | epigenome | - |
| dc.subject | hypomethylating agents | - |
| dc.subject | myelodysplastic syndrome/neoplasm (MDS) | - |
| dc.title | Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm? | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1111/bjh.19441 | - |
| dc.identifier.scopus | eid_2-s2.0-85189073668 | - |
| dc.identifier.eissn | 1365-2141 | - |
| dc.identifier.isi | WOS:001194924600001 | - |
| dc.identifier.issnl | 0007-1048 | - |